Tolterodine Accord
Antimuscarinic agent for overactive bladder – reduces urgency, frequency and urge incontinence
Tolterodine Accord contains the active substance tolterodine tartrate, an antimuscarinic medication that relaxes the bladder muscle. It is prescribed for the treatment of overactive bladder (OAB) symptoms, including urinary urgency, increased frequency, and urge incontinence. This evidence-based guide covers uses, correct dosage, potential side effects, drug interactions, and storage based on international guidelines from the EMA, FDA, WHO, and AUA/SUFU.
Quick Facts
Key Takeaways
- Tolterodine Accord is a prescription antimuscarinic medication used to treat symptoms of overactive bladder such as urgency, frequent urination, and urge incontinence.
- The standard adult dose is 2 mg twice daily (immediate-release tablets), which may be reduced to 1 mg twice daily in patients with liver or kidney impairment or intolerable side effects.
- Dry mouth is the most common side effect, affecting more than 1 in 10 patients; other frequent effects include headache, dizziness, constipation, and dry eyes.
- Do not use tolterodine if you have urinary retention, uncontrolled narrow-angle glaucoma, myasthenia gravis, severe ulcerative colitis, or toxic megacolon.
- Allow 2–3 months for a full therapeutic evaluation; do not stop treatment prematurely as the bladder needs time to adjust.
What Is Tolterodine Accord and What Is It Used For?
Quick Answer: Tolterodine Accord is an antimuscarinic medication prescribed to treat overactive bladder (OAB). It works by blocking muscarinic receptors in the bladder wall, reducing involuntary muscle contractions and thereby decreasing urinary urgency, frequency, and episodes of urge incontinence.
Tolterodine tartrate, the active substance in Tolterodine Accord, belongs to a class of medicines called antimuscarinic (also known as anticholinergic) agents. These drugs act on the muscarinic receptors – specifically the M2 and M3 subtypes – found in the smooth muscle of the urinary bladder. By competitively blocking acetylcholine at these receptors, tolterodine reduces the frequency and intensity of involuntary detrusor muscle contractions that cause the hallmark symptoms of OAB.
Overactive bladder is a clinical syndrome characterised by urinary urgency, with or without urge incontinence, usually accompanied by increased daytime frequency and nocturia (waking at night to urinate). The International Continence Society (ICS) estimates that OAB affects approximately 12–17% of the adult population worldwide, with prevalence increasing with age. Although not life-threatening, OAB significantly impacts quality of life, social functioning, and mental health.
Unlike some older antimuscarinic agents, tolterodine was specifically designed for bladder selectivity. Clinical pharmacology studies have demonstrated that tolterodine has a higher functional selectivity for the bladder over the salivary glands compared to oxybutynin, which translates into a more favourable side-effect profile – particularly less dry mouth at therapeutic doses. This selectivity is partly due to its active metabolite, 5-hydroxymethyl tolterodine (5-HMT), which contributes significantly to the overall antimuscarinic activity.
Tolterodine Accord is available as film-coated tablets (1 mg and 2 mg) and as extended-release (depot) capsules. The extended-release formulation provides steady-state plasma levels over 24 hours, allowing once-daily dosing and potentially fewer peak-related side effects. The immediate-release tablet formulation is taken twice daily. Both formulations have been shown in randomised controlled trials to significantly reduce the number of urge incontinence episodes, micturitions per day, and urgency episodes compared with placebo.
What Should You Know Before Taking Tolterodine Accord?
Quick Answer: Before starting tolterodine, tell your doctor about all medical conditions – especially urinary retention risk, glaucoma, heart problems, or liver/kidney disease. This medication is contraindicated in several conditions and interacts with many other drugs.
Contraindications
Tolterodine Accord must not be used in the following circumstances. These are absolute contraindications, meaning the risk of harm clearly outweighs any potential benefit:
- Hypersensitivity – Allergy to tolterodine tartrate or any of the excipients
- Urinary retention – Inability to empty the bladder
- Uncontrolled narrow-angle glaucoma – Raised intraocular pressure not under optimal control
- Myasthenia gravis – A condition causing significant muscle weakness
- Severe ulcerative colitis – Active severe inflammation of the large bowel
- Toxic megacolon – Acute dilation of the colon
Warnings and Precautions
Speak with your doctor before taking Tolterodine Accord if any of the following apply to you. These conditions do not necessarily prevent you from taking the medication, but they require careful monitoring and possibly dose adjustment:
- Difficulty urinating or weak urine stream – Tolterodine may worsen urinary retention, particularly in patients with bladder outflow obstruction (e.g., benign prostatic hyperplasia).
- Gastrointestinal disorders – Conditions affecting gastric motility or digestion, including gastroparesis, as tolterodine can slow gastrointestinal transit.
- Kidney or liver disease – Impaired renal or hepatic function can increase plasma levels of tolterodine, necessitating dose reduction (see Dosage section).
- Autonomic neuropathy – Nerve disorders affecting blood pressure, bowel, or sexual function.
- Hiatal hernia (diaphragmatic hernia) – Tolterodine may worsen gastro-oesophageal reflux.
- Severe constipation or reduced gastrointestinal motility – The anticholinergic effect can exacerbate these conditions.
- Cardiac conditions including:
- Abnormal electrocardiogram (ECG), particularly QT prolongation
- Bradycardia (slow heart rate)
- History of cardiomyopathy (weakened heart muscle)
- Myocardial ischaemia (reduced blood flow to the heart)
- Arrhythmia (irregular heartbeat)
- Heart failure
- Electrolyte abnormalities – Low levels of potassium (hypokalaemia), calcium (hypocalcaemia), or magnesium (hypomagnesaemia) in the blood, which increase the risk of QT prolongation.
Older adults may be more susceptible to antimuscarinic side effects, including cognitive impairment, confusion, and falls. The American Geriatrics Society Beers Criteria lists anticholinergic drugs – including tolterodine – as potentially inappropriate for older adults. Discuss the benefits versus risks with your healthcare provider, and report any changes in memory, orientation, or balance promptly.
Pregnancy and Breastfeeding
Pregnancy: Tolterodine Accord should not be used during pregnancy. There are insufficient data on the use of tolterodine in pregnant women, and animal studies have shown reproductive toxicity at high doses. If you are pregnant, think you may be pregnant, or are planning a pregnancy, inform your doctor immediately before taking this medicine.
Breastfeeding: It is unknown whether tolterodine or its metabolites are excreted in human breast milk. Breastfeeding is therefore not recommended during treatment with Tolterodine Accord. Your doctor will help you weigh the benefit of breastfeeding against the benefit of treatment.
Driving and Using Machines
Tolterodine can cause dizziness, drowsiness, and blurred vision, all of which may impair your ability to drive or operate machinery safely. You should assess your own fitness before driving or performing tasks requiring alertness. If you experience any of these side effects, avoid driving until they resolve. Discuss any concerns with your doctor or pharmacist.
Tolterodine Accord film-coated tablets contain less than 1 mmol (23 mg) sodium per tablet, meaning they are essentially sodium-free. This is relevant for patients on a controlled sodium diet.
How Does Tolterodine Accord Interact with Other Drugs?
Quick Answer: Tolterodine is metabolised primarily by the liver enzyme CYP2D6, with CYP3A4 as an alternative pathway. Potent inhibitors of these enzymes (such as certain antibiotics, antifungals, and HIV drugs) can significantly increase tolterodine levels, leading to an increased risk of side effects. Concomitant use with QT-prolonging drugs requires particular caution.
Always tell your doctor or pharmacist about all medicines you are taking, including over-the-counter products and herbal supplements. Tolterodine tartrate can both affect and be affected by other medications. The following table summarises the most clinically significant interactions:
Major Interactions – Not Recommended
Concomitant use of tolterodine with the following drugs is not recommended due to the risk of significantly elevated plasma concentrations of tolterodine:
| Drug / Class | Mechanism | Clinical Significance |
|---|---|---|
| Erythromycin, Clarithromycin | Potent CYP3A4 inhibitors | Markedly increase tolterodine plasma levels; increased risk of QT prolongation and antimuscarinic toxicity |
| Ketoconazole, Itraconazole | Potent CYP3A4 inhibitors | Can double or triple tolterodine exposure; significant overdose risk |
| HIV protease inhibitors (e.g., ritonavir) | CYP3A4 and CYP2D6 inhibition | Substantial increase in tolterodine exposure; avoid combination |
Moderate Interactions – Use with Caution
The following drugs may be used with tolterodine under medical supervision, but require careful monitoring and possible dose adjustment:
| Drug / Class | Mechanism | Clinical Significance |
|---|---|---|
| Amiodarone, Sotalol, Quinidine, Procainamide | QT-prolonging antiarrhythmics | Additive risk of QT prolongation and potentially fatal cardiac arrhythmias (torsades de pointes) |
| Metoclopramide, Cisapride | Prokinetic agents | Opposing pharmacological effects; tolterodine may reduce the efficacy of these drugs, and cisapride adds QT risk |
| Other antimuscarinics (oxybutynin, solifenacin, etc.) | Additive anticholinergic effects | Increased risk of dry mouth, constipation, urinary retention, cognitive impairment, and heat stroke |
| Cholinergic agents (e.g., pilocarpine, donepezil) | Opposing pharmacological action | Mutual reduction of therapeutic effect; particularly important in patients taking cholinesterase inhibitors for dementia |
| Fluoxetine, Paroxetine | CYP2D6 inhibitors | May increase tolterodine plasma levels in CYP2D6 extensive metabolisers; consider dose reduction |
Tolterodine Accord can be taken before, during, or after meals – food does not significantly affect the overall absorption of tolterodine. However, grapefruit juice is a moderate CYP3A4 inhibitor and may modestly increase tolterodine plasma levels; regular consumption of large amounts should be discussed with your doctor.
What Is the Correct Dosage of Tolterodine Accord?
Quick Answer: The standard adult dose is one 2 mg film-coated tablet taken twice daily. For patients with impaired liver or kidney function, or those experiencing troublesome side effects, the dose is reduced to 1 mg twice daily. Extended-release capsules are taken as 4 mg once daily (or 2 mg once daily in reduced-dose patients).
Always take Tolterodine Accord exactly as your doctor has instructed. Do not change your dose without consulting your healthcare provider. Swallow the tablets whole with water – do not crush, chew, or break them.
Adults
Immediate-Release Tablets
Standard dose: 2 mg twice daily (morning and evening)
Reduced dose: 1 mg twice daily – for patients with hepatic or renal impairment, or if side effects are troublesome
Extended-Release Capsules
Standard dose: 4 mg once daily, swallowed whole
Reduced dose: 2 mg once daily – for hepatic or renal impairment, CYP2D6 poor metabolisers, or concomitant potent CYP3A4 inhibitors
Children and Adolescents
Tolterodine Accord is not recommended for use in children and adolescents under 18 years of age. Clinical trials in the paediatric population have not demonstrated a favourable benefit-risk balance. The European Medicines Agency (EMA) has waived the requirement for studies in children under 2 years and determined that available data do not support use in children aged 2–17 years for overactive bladder treatment.
Elderly Patients
No specific dose adjustment is required solely based on age. However, elderly patients are more susceptible to antimuscarinic side effects (particularly cognitive effects, dizziness, and falls), and the prescribing clinician should consider starting at the lower dose of 1 mg twice daily. The American Geriatrics Society (AGS) Beers Criteria recommend caution when prescribing anticholinergic agents to older adults due to the cumulative anticholinergic burden, which has been associated with increased risk of dementia, delirium, and cognitive decline.
| Patient Group | Immediate-Release | Extended-Release | Notes |
|---|---|---|---|
| Adults (standard) | 2 mg twice daily | 4 mg once daily | Take with or without food |
| Hepatic impairment | 1 mg twice daily | 2 mg once daily | Reduced clearance increases exposure |
| Renal impairment | 1 mg twice daily | 2 mg once daily | GFR <30 mL/min: use with caution |
| Elderly | 1–2 mg twice daily | 2–4 mg once daily | Consider starting low; monitor cognition |
| Children (<18 years) | Not recommended | Not recommended | Insufficient efficacy/safety data |
Missed Dose
If you forget a dose, take it as soon as you remember – unless it is nearly time for your next scheduled dose. In that case, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a forgotten one. If you are uncertain, contact your doctor or pharmacist for advice.
Overdose
If you or someone else has taken too much Tolterodine Accord, contact emergency services or a poison control centre immediately. Overdose symptoms may include:
- Hallucinations and severe agitation (CNS toxicity)
- Seizures or severe excitation
- Breathing difficulties
- Tachycardia (rapid heart rate)
- Urinary retention (inability to urinate)
- Mydriasis (dilated pupils)
- QT prolongation (ECG change that may lead to dangerous arrhythmias)
Treatment Duration
Your doctor will advise you on how long to continue taking Tolterodine Accord. Do not stop treatment prematurely, even if you do not notice immediate improvement, because the bladder needs time to adapt to the medication. Clinical guidelines recommend re-evaluating the treatment benefit after 2 to 3 months. If there has been no meaningful improvement by that time, discuss alternative treatment strategies with your doctor. Always consult your physician before discontinuing therapy.
What Are the Side Effects of Tolterodine Accord?
Quick Answer: The most common side effect is dry mouth, reported by more than 1 in 10 patients. Other frequently reported effects include headache, dizziness, drowsiness, constipation, dry eyes, blurred vision, and abdominal pain. Serious but uncommon effects include angioedema, heart failure, and severe allergic reactions.
Like all medicines, Tolterodine Accord can cause side effects, although not everybody experiences them. Most side effects are mild to moderate and tend to diminish as the body adjusts to the medication. The frequency categories below are based on clinical trial data and post-marketing surveillance, reported according to the standard MedDRA classification.
- Angioedema – Swelling of the face, tongue, or throat; difficulty swallowing; hives with breathing difficulty
- Signs of heart failure – Chest pain, breathlessness (including at rest or at night), significant fatigue, swollen legs
- Severe allergic reaction – Widespread rash, itching, difficulty breathing
Very Common
Affects more than 1 in 10 patients
- Dry mouth (xerostomia)
- Headache
Common
Affects 1 in 10 to 1 in 100 patients
- Dizziness and vertigo
- Drowsiness (somnolence)
- Dry eyes
- Blurred vision
- Palpitations (sensation of heartbeat)
- Abdominal pain
- Constipation
- Dyspepsia (indigestion)
- Nausea and vomiting
- Diarrhoea
- Flatulence
- Dry skin
- Painful or difficult urination (dysuria)
- Urinary retention (inability to empty bladder)
- Fatigue
- Chest pain
- Peripheral oedema (swelling, e.g., ankles)
- Weight gain
- Bronchitis
- Paraesthesia (tingling in fingers/toes)
Uncommon
Affects 1 in 100 to 1 in 1,000 patients
- Allergic reactions
- Anxiety and nervousness
- Irregular heart rate (arrhythmia)
- Tachycardia (increased heart rate)
- Heart failure
- Heartburn (gastro-oesophageal reflux)
- Memory impairment
Rare / Post-Marketing Reports
Affects fewer than 1 in 1,000 patients (or reported post-marketing)
- Severe allergic (anaphylactoid) reactions
- Confusion and disorientation
- Hallucinations (visual, auditory, olfactory, gustatory, or tactile)
- Skin flushing
- Angioedema
- Worsening of dementia symptoms (in patients treated for dementia)
If you experience any side effects, including any not listed above, talk to your doctor or pharmacist. You can also report side effects directly to your national pharmacovigilance authority (e.g., FDA MedWatch in the US, Yellow Card Scheme in the UK, or the EMA in Europe). By reporting side effects, you help provide more information on the safety of this medicine.
Anticholinergic (antimuscarinic) side effects are dose-dependent and often improve with time or dose reduction. If dry mouth is particularly troublesome, strategies such as sugar-free gum, frequent small sips of water, and saliva substitutes can help. Switching from immediate-release to extended-release formulation may also reduce the incidence and severity of dry mouth, as clinical trials have shown a lower rate with the sustained-release capsule.
How Should You Store Tolterodine Accord?
Quick Answer: Store Tolterodine Accord at room temperature in its original packaging. Keep out of sight and reach of children. Do not use after the expiry date printed on the packaging.
Keep this medicine out of the sight and reach of children at all times. No special storage conditions are required – store at room temperature (below 25°C / 77°F) in the original blister packaging to protect from moisture.
Do not use Tolterodine Accord after the expiry date stated on the blister pack and carton. The expiry date refers to the last day of that month. Check the expiry date before taking each dose.
Do not dispose of medicines via household waste or wastewater. Return unused or expired medicines to your pharmacist for safe disposal. These measures help protect the environment and prevent accidental exposure.
What Does Tolterodine Accord Contain?
Quick Answer: The active substance is tolterodine tartrate (1 mg or 2 mg per tablet, equivalent to 0.68 mg or 1.37 mg tolterodine respectively). Inactive ingredients include microcrystalline cellulose, sodium starch glycolate, magnesium stearate, and a film-coating composed of hypromellose, titanium dioxide, macrogol, and talc.
Active Substance
- 1 mg tablets: Each tablet contains 1 mg tolterodine tartrate, equivalent to 0.68 mg tolterodine
- 2 mg tablets: Each tablet contains 2 mg tolterodine tartrate, equivalent to 1.37 mg tolterodine
Inactive Ingredients (Excipients)
Tablet core: Microcrystalline cellulose, sodium starch glycolate (type A), magnesium stearate, colloidal anhydrous silica.
Film-coating: Hypromellose (E464), titanium dioxide (E171), macrogol 8000, talc (E553b).
Tablet Appearance
1 mg tablets: White to off-white, round, approximately 6.35 mm in diameter, biconvex, film-coated tablets, debossed with “S16” on one side.
2 mg tablets: White to off-white, round, approximately 6.35 mm in diameter, biconvex, film-coated tablets, debossed with “S042” on one side.
Pack Sizes
Tolterodine Accord is available in blister packs of 14, 20, 28, 30, 50, 56, 60, 90, and 100 film-coated tablets. Not all pack sizes may be marketed in your country.
Accord Healthcare B.V., Winthontlaan 200, 3526 KV Utrecht, The Netherlands.
Frequently Asked Questions About Tolterodine Accord
Tolterodine Accord is used to treat symptoms of overactive bladder (OAB), including urinary urgency (a sudden, compelling need to urinate), increased frequency of urination (going to the toilet more often than normal), and urge incontinence (involuntary urine leakage associated with urgency). It works by relaxing the detrusor muscle of the bladder, increasing bladder capacity and reducing involuntary contractions.
The standard dosage for adults is one 2 mg film-coated tablet taken twice daily (morning and evening). For patients with impaired liver or kidney function, or those experiencing troublesome side effects, the dose may be reduced to 1 mg twice daily. The extended-release capsule formulation is taken as 4 mg once daily. Always follow your doctor's prescribed dose.
The most common side effects are dry mouth (affecting more than 1 in 10 patients) and headache. Other frequently reported side effects include dizziness, drowsiness, dry eyes, blurred vision, constipation, abdominal pain, and fatigue. Most side effects are mild and may improve as your body adjusts to the medication. If any side effect becomes severe or persistent, consult your doctor.
Tolterodine Accord should not be used during pregnancy due to insufficient safety data and evidence of reproductive toxicity in animal studies at high doses. It is also not recommended during breastfeeding, as it is unknown whether tolterodine passes into breast milk. If you are pregnant, suspect pregnancy, or are planning to become pregnant, inform your doctor immediately.
Tolterodine may take several weeks to reach its full therapeutic effect because the bladder needs time to adjust. You should not stop treatment early even if you do not see immediate improvement. Clinical guidelines recommend re-evaluating the treatment benefit after 2 to 3 months. If no meaningful improvement has occurred by then, discuss alternative options with your doctor.
You should not take tolterodine concurrently with potent CYP3A4 inhibitors such as certain antibiotics (erythromycin, clarithromycin), antifungal agents (ketoconazole, itraconazole), or HIV protease inhibitors (e.g., ritonavir). Use caution with antiarrhythmic drugs that prolong the QT interval (amiodarone, sotalol, quinidine), other antimuscarinic agents, and cholinesterase inhibitors used for dementia (donepezil, rivastigmine). Always inform your doctor about all medications you are taking.
References
All medical information on this page is based on peer-reviewed research, international clinical guidelines, and official regulatory documents. The following sources were consulted:
- European Medicines Agency (EMA). Tolterodine – Summary of Product Characteristics (SmPC). European Public Assessment Reports. Available at: www.ema.europa.eu
- U.S. Food and Drug Administration (FDA). Detrol / Detrol LA (tolterodine tartrate) – Prescribing Information. FDA Label Archives.
- Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. European Urology. 2008;54(3):543–562. doi:10.1016/j.eururo.2008.06.047
- Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Neurourology and Urodynamics. 2002;21(2):167–178.
- Gormley EA, Lightner DJ, Burgio KL, et al. AUA/SUFU Guideline on the Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults. Journal of Urology. 2019;202(3):558–563.
- National Institute for Health and Care Excellence (NICE). Urinary incontinence and pelvic organ prolapse in women: management. NICE guideline [NG123]. 2019.
- By the 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. Journal of the American Geriatrics Society. 2023;71(7):2052–2081.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List, 2023. Geneva: World Health Organization.
- Nitti VW, Dmochowski R, Herschorn S, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo-controlled trial. Journal of Urology. 2013;189(6):2186–2193.
- Andersson KE, Chapple CR, Cardozo L, et al. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Current Opinion in Urology. 2009;19(4):380–394.
Medical Editorial Team
All content on iMedic is written and reviewed by qualified medical professionals. Our editorial process follows international standards for medical content creation, including the GRADE evidence framework and adherence to guidelines from WHO, EMA, FDA, and relevant specialist societies.
iMedic Medical Editorial Team – Specialists in Urology, Clinical Pharmacology, and Internal Medicine
iMedic Medical Review Board – Independent panel following GRADE evidence framework and international clinical guidelines
Last medical review:
Evidence level: 1A – Based on systematic reviews of randomised controlled trials and international clinical guidelines.
Conflict of interest: None. iMedic receives no commercial funding and has no pharmaceutical sponsorship.